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Abstract. – OBJECTIVE: Curcumin is known
to interrupt pro-inflammatory signalling and in-
creases anti-oxidant protection, thus inhibiting
the expression of inflammatory cytokines and
the expression and function of inducible inflam-
matory enzymes. Together, these effects con-
tribute to limit the onset and the progression of
sarcopenia, due to the major role played by in-
flammation in the pathophysiology of this dis-
ease. This registry study evaluates the effects of
Meriva® supplementation in otherwise healthy
elderly subjects.
PATIENTS AND METHODS: This was a reg-
istry, supplement study, conducted in healthy
subjects > 65 years with apparent loss of
strength and tiredness who freely decided to
start one of the following interventions: (1) stan-
dard management (exercise, balanced diet in-
cluding proteins) (n = 33); (2) standard manage-
ment + Meriva® one tablet/day (n = 31); (3) stan-
dard management + Meriva® one tablet/day +
other supplementation (n = 22). A number of
functional and biochemical parameters were
evaluated at baseline and after three months
(hand grip, weight lifting, time/distance before
feeling tired after cycling, walking and climbing
stairs; general fitness, proteinuria, oxidative
stress, Karnofsky scale; left ventricular ejection
fraction).
RESULTS: Significant improvements in all pa-
rameters, with respect to baseline values, were
observed in the two supplementation groups (p
< 0.05 for all comparisons). On the other hand,
no improvement was observed in the standard
management-only group. At three months, inter-
group comparison revealed a statistical advan-
tage in all parameters for both supplementation
groups compared with the standard manage-
ment-only group (p < 0.05 for all comparisons).
CONCLUSIONS: Our registry study shows
that the addition of Meriva® – either or not com-
bined with other nutritional supplements – to
standardized diet and exercise plan contributes
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Introduction
Sarcopenia is a decrease in muscle mass often
related with age or pathological conditions1,2.
Due to increasing age of population, the preva-
lence of sarcopenia is increasing in Western
countries. Moreover, sarcopenia can progress in
its severity and impair the ability to perform
daily acrivities, with a marked impact on quali-
ty of life1,2. Eventually, sarcopenia may lead to
an increased risk of disability, falls and hospital-
ization3.
Besides life style-related factors, as diet and
physical activity, other mechanisms underlying
the development of sarcopenia are not complete-
ly understood. However, they are thought to be
multi-factorial, with chronic inflammation status
playing a crucial role4. 
Nutritional interventions may provide an im-
portant contribution to prevent the development
of sarcopenia1. Among different nutritional inter-
ventions, curcumin is known to exert a pleiotrop-
ic effect. Curcumin interrupts pro-inflammatory
signalling and increases anti-oxidant protection
by acting at distinct time-domain targets: (1)
short time-domain targets such as pro-inflamma-
tory enzymes (mPGES-1, 5-LO), and ion chan-
nels (TRPV1, TRPA1), and (2) long time-do-
main targets such as pro-inflammatory transcrip-
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Endurance Cycling/Walinkg/Climbing stairs until exaustion Daily
Strenght Lifting low weights 20 × arm, 20 × leg, three times daily
Balance Walk along a 5-meter line Daily
Flexibility All main joints 20 second×joint, twice daily
Table I. Exercise program, performed every day.
decided, after consultation at our Center for ap-
parent loss of strength and tiredness, to start one
of the following interventions: (1) standard man-
agement: exercise (Table I), balanced diet in-
cluding proteins (both according to the instruc-
tions of trained specialists); (2) Group B: stan-
dard management + Meriva® one tablet/day
(each tablet containing 1 g Meriva®); (3) stan-
dard management + Meriva® one tablet/day +
other supplementation (Vitamin D 800 IU/day;
Vitamin C 500 mg/day; Isoleucin 3 g/day;
Carinitine 1 g/day). The participants were visited
at baseline and after three months. No other
treatments were needed or used during the obser-
vation period. All patients had a completely no-
mal cardiovascular system (as shown by ultra-
sound evaluation before inclusion).
The following evaluations were performed at
baseline and at the end of the observation period:
(1) hand grip, using standard digital Jamar dy-
namometers (Patterson Medical, Warrenvile, IL,
USA) and assessed as the sum of three consecu-
tive measurements in 1 minute; (2) weight lift-
ing, assessed as the number of times the subject
can lift a 2 kg manuber; (3) time/distance before
feeling tired after cycling, walking and climbing
stairs; (4) general fitness, by a numerical scale (0
= unable to move; 3 = normal); (5) proteinuria;
(6) oxidative stress measurements, according
to24,25; (7) Karnofsky scale; (8) measurement of
left ventricular ejection fraction by ultrasounds.
Basic blood tests and the physiological para-
meters were also evaluated at inclusion and at the
end of the observational period.
Statistical Analysis
Data were analyzed by descriptive statistics.
Intra- and inter-group comparisons were per-
formed by the Mann-Witney test. A p value <
0.05 was considered statistically significant.
Results
In total, 86 registry subjects were followed up.
Of these, 33 decided to follow standard manage-
tion factors (NF-kB, AP1, STAT, PPAR-g). As a
net result, curcumin inhibits the expression of in-
flammatory cytokines (TNF-a, IL-1b, IL-6) and
of the expression and function of inducible in-
flammatory enzymes (COX2 and mPG2S)5-7. In
particular, NF-kB is involved in the development
of muscle wasting during catabolic conditions
such as sarcopenia; animal studies have shown
that inhibition of NF-kB activity in skeletal mus-
cle allows reducing protein degradation8. A simi-
lar effect is associated with the inhibition of oth-
er pro-inflammatory enzymes exerted by cur-
cumin8. Moreover, curcumin contributes to re-
duce the inflammatory burden leading to muscle
loss in sarcopenia patients by inducing an inhibi-
tion of p38 kinase activity, oxygen radical scav-
enging, and induction of the heat-shock re-
sponse8. Together, these effects, and in particular
the inhibition of NF-kB, do contribute to limit
the onset and the progression of sarcopenia8.
However, curcumin has a poor systemic
bioavailability9. Several attempts have been
made to overcome this limitation: in particular,
dispersion of active molecules (typically belong-
ing to the chemical class of polyphenols and
triterpenes) with phospholipids under appropriate
conditions leads to the formation of a delivery
form named Phytosome®10. Among these com-
plexes, the commercially available Phytosome®
of curcumin, named Meriva®, has been studied
for the treatment of a wide range of conditions
compared versus non-formulated Curcumin11-22.
On these bases, curcumin may represent a po-
tential nutritional intervention to control sarcope-
nia in affected subjects, in particular for elderly.
This registry study evaluates the effects of Meri-
va® supplementation in otherwise healthy elderly
subjects, in order to preliminarily evaluate its ef-
ficacy in the management of sarcopenia.
Patients and Methods
This was a registry, supplement study (see23
for a complete description of such studies), con-
ducted in healty subjects > 65 years who freely
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ment only, 31 standard management+Meriva®
and 22 took also the additional supplementation.
No significant differences among groups were
reported (Table II). No safety concerns or clini-
cally relevant variations of laboratory parameters
and vital signs were reported.
Table III summarizes the efficacy evaluations.
Overall, significant improvements in all parame-
ters, with respect to baseline values, were ob-
served in the two supplementation groups; on the
other hand, no improvement was observed in the
standard management only group. At three
months, inter-group comparison revealed a statis-
tical advantage in all parameters for both supple-
mentation groups compared with the standard
management only group.
Compliance to supplementation was good with
more than 95% of the supplements correctly used.
Discussion
Sarcopenia represents a major clinical issue,
given also the increasing prevalence of elderly
people in the general population. This clinical
condition can lead to a number of health prob-
lems, with a significant burden to the healthcare
system. 
It has been proposed that nutritional supple-
mentation can have a role in the prevention and
management of sarcopenia1. Our registry study,
conducted in healty elderly subjects complaining
for strength loss and physical tiredness, lends
further support to this assumption. 
In fact, the addition, to standardized diet and
exercise, of nutritional supplementation with
Meriva®, either or not combined with other sup-
plements, resulted in statistically significant and
Standard
Standard Standard management + Meriva® +
management only management + Meriva® additional supplementation
Subjects 33 31 22
Females 16 14 12
Age, years (mean ± SD) 72 (2) 74 (1) 73 (1)
BMI, kg/m2 24.7 (1.0) 24.3 (1.5) 24.3 (1.2)
Table II. Basline characteristics.
SD: standard deviation.
Standard
Standard Standard management + Meriva® +
management only management + Meriva® additional supplementation
(n = 33) (n = 31) (n = 22)
Baseline 3 months Baseline 3 months Baseline 3 months
Hand grip, kg 32.2 (2.1) 31.8 (2.0) 31.2 (1.5) 33.9 (1.8)* 32.8 (1.7) 35.4 (1.1)*
Weight lifting 12 (2) 11 (1) 13 (1) 16 (2)* 11 (1) 16 (2)*
Time/distance before
eeling tired, minutes
(meters for the walking
test)
Cycling 2’ 20” (18”) 2’ 16” (12”) 2’ 29” (18”) 3’ 11” (11”)* 2’ 14” (13”) 3’ 44” (21”)*
Walking 234 (21) 239 (12) 251 (11) 311 (14)* 244 (18) 319 (24)*
Climbing stairs 58” (6”) 69” (5”) 54” (6”) 75” (3”)* 51” (5”) 69” (2”)*
General fitness, score 1.1 1.1 1.2 2.2* 1.1 2.5*
Proteinuria, mg/die 244 (37) 239 (46) 239 (28) 154 (39)* 233 (34) 158 (39)*
Oxidative stress, carr units 368 (24) 359 (26) 379 (31) 334 (26)* 377 (28)* 336 (23)*
Karnofsky scale, units 75.4 (3.2) 72.2 (1.3) 76.2 (3.4) 81.1 (2.0)* 75.3 (1.8) 83.4 (2.2)*
Left ventricular 54.8 (0.2) 55 (0.4) 56.2 (0.5) 59.8 (0.3)* 57.1 (0.6) 62.4 (1.0)*
ejection fraction, %
Table III. Efficacy evaluations. All data are expressed as mean (SD).
*p < 0.05 vs. baseline and vs. standard management-only.
clinically relevant improvements in a number of
functional and physiological parameters without
any safety concern. On the other hand, stardard
management only was not associated with any sig-
nificant improvement over a 3 months’ period. 
Our findings can be due, at least in part, to the
recognized anti-inflammatory effects of Meri-
va®5,6,8, which target systemic inflammation, one
of the main contributors to the onset of sarcope-
nia4. Moreover, in animal models curcumin was
shown to promote protein regeneration and re-
duce muscle loss26.
Remarkably, subjects who decided to take
supplementation reported a reduction of oxida-
tive stress, which remains a major determinant of
sarcopenia development. This kind of cellular
damage has a role in enhancing tiredness and
weakness, also in healty subjects27,28, overall po-
tentially contributing to the onset of sarcopenia.
Further studies on the effect of oxidative stress
and anti-oxidant compounds in sarcopenia pa-
tients can be of the highest interest. Moreover,
the effects of nutritional supplementation were
also evident in improving left ventricular ejection
fraction: while all subjects had normal values of
this parameter at baseline, this finding may sug-
gest more specific studies in patients with im-
paired left ventricular function.
Conclusions
Our registry study shows that the addition of
Meriva® – either or not combined with other nu-
tritional supplements – to standardized diet and
exercise plan contributes to improve strenght and
physical performance in elderly subjects, poten-
tially preventing the onset of sarcopenia. We be-
lieve that Meriva®, in the context of an integrated
approach29-33, holds the potential to have a role in
the management of this condition.
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